JP2014218496A - Highly-preservable antibody solution - Google Patents
Highly-preservable antibody solution Download PDFInfo
- Publication number
- JP2014218496A JP2014218496A JP2014079671A JP2014079671A JP2014218496A JP 2014218496 A JP2014218496 A JP 2014218496A JP 2014079671 A JP2014079671 A JP 2014079671A JP 2014079671 A JP2014079671 A JP 2014079671A JP 2014218496 A JP2014218496 A JP 2014218496A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antibody solution
- mass
- egg yolk
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 68
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 34
- 230000001954 sterilising effect Effects 0.000 claims abstract description 22
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 102000002322 Egg Proteins Human genes 0.000 claims description 28
- 108010000912 Egg Proteins Proteins 0.000 claims description 28
- 235000013345 egg yolk Nutrition 0.000 claims description 28
- 239000007921 spray Substances 0.000 claims description 9
- 239000003125 aqueous solvent Substances 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 239000003205 fragrance Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003755 preservative agent Substances 0.000 abstract description 7
- 239000003381 stabilizer Substances 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000002335 preservative effect Effects 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 59
- 239000013566 allergen Substances 0.000 description 13
- 238000003860 storage Methods 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 241000282373 Panthera pardus Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- NZGWDASTMWDZIW-MRVPVSSYSA-N (+)-pulegone Chemical compound C[C@@H]1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-MRVPVSSYSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000256111 Aedes <genus> Species 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- NZGWDASTMWDZIW-UHFFFAOYSA-N Pulegone Natural products CC1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-UHFFFAOYSA-N 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- USMNOWBWPHYOEA-UHFFFAOYSA-N alpha-thujone Natural products CC1C(=O)CC2(C(C)C)C1C2 USMNOWBWPHYOEA-UHFFFAOYSA-N 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229930007459 p-menth-8-en-3-one Natural products 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
この発明は、防腐剤や安定化剤等を用いなくても、卵黄抗体の活性を維持しつつ長期にわたり常温で保存できる高保存性抗体溶液、その製造方法、及び、抗体の保存方法に関するものである。 The present invention relates to a highly-storable antibody solution that can be stored at room temperature for a long period of time while maintaining the activity of egg yolk antibodies without using preservatives, stabilizers, etc., a method for producing the same, and a method for storing antibodies. is there.
従来、マスクに抗菌性や抗ウイルス性等を付与するために、細菌やウイルスに由来する抗原に対する抗体が担持されたマスクが知られているが(特許文献1)、より手軽にマスクに抗菌性や抗ウイルス性等を付与できるように、マスクに抗体溶液を吹き付けるためのスプレーも知られている。このようなスプレーでは、使用時に粉末状の抗体を水道水等に溶解して抗体溶液を調製し、当該抗体溶液をマスクに向けて噴霧するように構成されている。しかし、粉末状の抗体を用いると、使用の度に水道水等に溶解する必要があるため作業が煩雑となり、使いやすさの点から、予め調製された抗体溶液が充填されているスプレーが求められている。 Conventionally, in order to impart antibacterial and antiviral properties to a mask, a mask in which an antibody against an antigen derived from a bacterium or virus is supported is known (Patent Document 1). A spray for spraying an antibody solution onto a mask is also known so that it can be imparted with antiviral properties and antiviral properties. In such a spray, a powdered antibody is dissolved in tap water or the like at the time of use to prepare an antibody solution, and the antibody solution is sprayed toward a mask. However, when powdered antibodies are used, it is necessary to dissolve them in tap water each time they are used, and the work becomes complicated. From the viewpoint of ease of use, a spray filled with a preliminarily prepared antibody solution is required. It has been.
ところで、抗原抗体反応には、抗体の可変領域等の立体構造が重要であるため、抗体を保存するに際しては、このような立体構造が壊れないように注意を要する。しかし、抗体の立体構造は、温度、化学物質等の影響を受けやすく、とりわけ液体中において活性を維持した状態で抗体を長期間保存することは困難である。このため、液体中の抗体を安定化する様々な方法が検討されている。このような安定化方法としては、例えば、特許文献2には、IgM試薬溶液にウシ血清アルブミン(BSA)を添加する方法が提案されており、また、抗体溶液にポリエチレングリコールを添加する方法も知られている。更に、抗体溶液の腐敗を防止するために、通常、抗体溶液にはアジ化ナトリウム等の防腐剤も添加されている。このような抗体溶液は、通常4℃程度の低温で保存される。 By the way, since the three-dimensional structure such as the variable region of the antibody is important for the antigen-antibody reaction, care must be taken when storing the antibody so that the three-dimensional structure is not broken. However, the three-dimensional structure of an antibody is easily affected by temperature, chemical substances, etc., and it is difficult to store the antibody for a long period of time, particularly while maintaining the activity in a liquid. For this reason, various methods for stabilizing antibodies in a liquid have been studied. As such a stabilization method, for example, Patent Document 2 proposes a method of adding bovine serum albumin (BSA) to an IgM reagent solution, and also known a method of adding polyethylene glycol to an antibody solution. It has been. Furthermore, in order to prevent the antibody solution from decaying, an antiseptic such as sodium azide is usually added to the antibody solution. Such an antibody solution is usually stored at a low temperature of about 4 ° C.
また、マスクに抗菌性や抗ウイルス性を付与するための抗体としては、卵黄抗体(IgY:immunoglobulin yolk)が用いられることが多い。卵黄抗体は、鳥類の血液中のIgGが卵黄中に移行したものであり、特定の抗原でニワトリ等の鳥類を免疫すると、卵黄からその抗原に特異的な抗体を得ることができる。このように鳥類の卵から抗体を調製する方法には、抗体を大量に調製できること、採血が不要なこと、大量飼育が容易であること、卵黄からの精製は比較的簡単であること等の利点がある。しかし、卵黄抗体は哺乳類のIgGとは物理的化学的な性状が異なることが知られている。 Further, as an antibody for imparting antibacterial and antiviral properties to the mask, an egg yolk antibody (IgY: immunooglobulin yolk) is often used. The egg yolk antibody is obtained by transferring IgG in the blood of birds into the egg yolk. When a bird such as a chicken is immunized with a specific antigen, an antibody specific to the antigen can be obtained from the egg yolk. Thus, the method for preparing antibodies from avian eggs has advantages such as the ability to prepare antibodies in large quantities, the need for blood collection, ease of mass breeding, and the relatively simple purification from egg yolk. There is. However, egg yolk antibodies are known to have different physical and chemical properties from mammalian IgG.
そこで本発明は、防腐剤や安定化剤等を用いなくても、卵黄抗体の活性を維持しつつ長期にわたり常温で保存できる高保存性抗体溶液、その製造方法、及び、抗体の保存方法を提供すべく図ったものである。 Therefore, the present invention provides a highly-storable antibody solution that can be stored at room temperature for a long period of time while maintaining the activity of egg yolk antibody without using preservatives, stabilizers, etc., a method for producing the same, and a method for storing the antibody It was something that was planned.
本発明者らは、所定濃度になるようにエタノールを添加し、かつ、滅菌処理を施すことにより、安定化剤や防腐剤等を用いなくとも、卵黄抗体を水溶液中において安定な状態で長期にわたり保存できることを見出した。本発明は、この知見に基づき完成するに至ったものである。 By adding ethanol to a predetermined concentration and applying sterilization, the present inventors can maintain the egg yolk antibody in an aqueous solution in a stable state over a long period of time without using a stabilizer or preservative. I found that it can be saved. The present invention has been completed based on this finding.
すなわち本発明に係る高保存性抗体溶液は、卵黄抗体と、水と、1〜25質量%のエタノールとを含有し、滅菌処理が施されていることを特徴とする。 That is, the highly conserved antibody solution according to the present invention contains egg yolk antibody, water, and 1 to 25% by mass of ethanol, and is sterilized.
このようなものであれば、滅菌処理が施されているので、調製直後は細菌等の混入は抑えられており、また、調製してから時間が経過して若干の細菌等が混入しても、エタノールにより細菌等の繁殖を抑えることができる。 In such a case, since sterilization is performed, contamination of bacteria and the like is suppressed immediately after the preparation, and even if some bacteria or the like are mixed in after a lapse of time after preparation. The growth of bacteria and the like can be suppressed by ethanol.
前記滅菌処理としては、例えば、フィルター滅菌が好適に用いられる。 As the sterilization treatment, for example, filter sterilization is preferably used.
本発明に係る高保存性抗体溶液は、香料や緩衝剤等を含有していてもよい。 The highly conserved antibody solution according to the present invention may contain a fragrance, a buffering agent and the like.
本発明に係る高保存性抗体溶液は、マスク等に抗菌性や抗ウイルス性を付与するためのスプレー用充填液として好適に用いられる。すなわち本発明に係る高保存性抗体溶液が充填されてなるスプレーもまた、本発明の一つである。 The highly conserved antibody solution according to the present invention is suitably used as a spray filling liquid for imparting antibacterial and antiviral properties to a mask or the like. That is, a spray filled with the highly conserved antibody solution according to the present invention is also one aspect of the present invention.
また、本発明に係る高保存性抗体溶液の製造方法もまた、本発明の一つである。すなわち本発明に係る高保存性抗体溶液の製造方法は、卵黄抗体を水性溶媒に溶解して抗体溶液を調製する工程と、前記抗体溶液をフィルター滅菌する工程と、フィルター滅菌が施される前又は後の抗体溶液に、1〜25質量%の濃度となるようにエタノールを加える工程と、を有することを特徴とする。 The method for producing a highly conserved antibody solution according to the present invention is also one aspect of the present invention. That is, the method for producing a highly-storable antibody solution according to the present invention includes a step of dissolving an egg yolk antibody in an aqueous solvent to prepare an antibody solution, a step of filter sterilizing the antibody solution, and before the filter sterilization is performed. Adding ethanol to the subsequent antibody solution to a concentration of 1 to 25% by mass.
更に、本発明に係る抗体の保存方法もまた、本発明の一つである。すなわち本発明に係る抗体の保存方法は、卵黄抗体を水性溶媒に溶解して抗体溶液を調製する工程と、前記抗体溶液をフィルター滅菌する工程と、フィルター滅菌が施される前又は後の抗体溶液に、1〜25質量%の濃度となるようにエタノールを加える工程と、前記抗体溶液を滅菌済みの密閉容器内に充填する工程と、を有することを特徴とする。 Furthermore, the method for preserving an antibody according to the present invention is also one aspect of the present invention. That is, the method for preserving an antibody according to the present invention includes a step of preparing an antibody solution by dissolving egg yolk antibody in an aqueous solvent, a step of filter sterilizing the antibody solution, and an antibody solution before or after filter sterilization is performed. And a step of adding ethanol to a concentration of 1 to 25% by mass and a step of filling the antibody solution in a sterilized sealed container.
このような構成を有する本発明によれば、防腐剤や安定化剤等を用いなくても、卵黄抗体を液体中において活性を維持しつつ長期にわたり常温で保存することが可能となる。 According to the present invention having such a configuration, it is possible to store an egg yolk antibody at room temperature for a long period of time while maintaining activity in a liquid without using a preservative or a stabilizer.
以下に本発明を詳述する。 The present invention is described in detail below.
本発明に係る高保存性抗体溶液は、卵黄抗体と、水と、1〜25質量%のエタノールとを含有し、滅菌処理が施されているものである。 The highly conserved antibody solution according to the present invention contains egg yolk antibody, water, and 1 to 25% by mass of ethanol, and has been sterilized.
前記卵黄抗体としては特に限定されないが、例えば、アレルゲン、ウイルス、細菌、カビ等に由来する抗原に対して結合能を有するものである。前記アレルゲンとしては、例えば、ダニアレルゲン、花粉、ネコアレルゲン等が挙げられる。前記ウイルスとしては、例えば、インフルエンザウイルス、コロナウイルス(SARSウイルス)、アデノウイルス、ライノウイルス等が挙げられる。前記細菌としては、例えば、黄色ブドウ球菌や表皮ブドウ球菌等のブドウ球菌属、ミクロコッカス属、炭疽菌、セレウス菌、枯草菌、アクネ菌等のグラム陽性菌;緑膿菌、セラチア菌、セパシア菌、肺炎球菌、レジオネラ菌、結核菌等のグラム陰性菌等が挙げられる。前記カビとしては、例えば、アスペルギルス、ペニシリウス、クラドスポリウム等が挙げられる。 Although it does not specifically limit as said egg yolk antibody, For example, it has a binding ability with respect to the antigen derived from allergen, a virus, bacteria, mold, etc. Examples of the allergen include mite allergen, pollen, cat allergen and the like. Examples of the virus include influenza virus, coronavirus (SARS virus), adenovirus, rhinovirus and the like. Examples of the bacteria include Gram-positive bacteria such as Staphylococcus aureus and Staphylococcus epidermidis, Micrococcus, Anthrax, Bacillus cereus, Bacillus subtilis and Acne; Pseudomonas aeruginosa, Serratia and Sephacia And Gram-negative bacteria such as Streptococcus pneumoniae, Legionella, and Mycobacterium tuberculosis. Examples of the mold include Aspergillus, Penicillius, and Cladosporium.
前記卵黄抗体を産生する鳥類としては特に限定されず、例えば、ニワトリ、ウズラ、アヒル、ダチョウ、ガチョウ、エミュー、七面鳥等が挙げられる。なかでも大量飼育が容易であり、安定かつ安価に卵黄抗体を産生できること等からニワトリが好適に用いられる。 The birds that produce the egg yolk antibody are not particularly limited, and examples thereof include chickens, quails, ducks, ostriches, geese, emu, and turkeys. Of these, chickens are preferably used because they are easily bred in large quantities and can produce egg yolk antibodies stably and inexpensively.
前記鳥類への免疫は、常法に従い行えばよく、目的の抗原を、必要に応じて適宜アジュバントと共に、鳥類に筋肉注射や皮下注射等の方法により接種する。前記アジュバントとしては、フロイントの完全アジュバント、フロイントの不完全アジュバント等を用いることができる。抗原やアジュバントの接種量、接種時期、接種回数は、目的の抗体が鳥類の体内で産生され、卵黄中に移行し所望の量が蓄積されるように適宜決定すればよい。また、卵黄中の抗体価を高めるために、追加免疫してもよい。 The bird may be immunized according to a conventional method, and the target antigen is inoculated to the bird together with an appropriate adjuvant as necessary by intramuscular injection, subcutaneous injection, or the like. As the adjuvant, Freund's complete adjuvant, Freund's incomplete adjuvant, or the like can be used. The inoculation amount, the inoculation time, and the inoculation number of the antigen and adjuvant may be appropriately determined so that the target antibody is produced in the body of the bird and moves into the yolk to accumulate a desired amount. In order to increase the antibody titer in egg yolk, booster immunization may be performed.
卵黄から抗体を精製する方法としては、公知の方法を用いることができ、例えば、超遠心分離法、有機溶剤脱脂による分離法、リポタンパク質凝集剤(ポリエチレングリコール、デキストラン硫酸ナトリウム、ポリアクリル酸樹脂、食品増粘安定剤等)を用いる方法、硫安沈澱等の塩析、限外濾過等の濾過、エタノールと超臨界炭酸ガス抽出を併用する脱脂法等が挙げられる。 As a method for purifying an antibody from egg yolk, a known method can be used. For example, ultracentrifugation, separation by organic solvent degreasing, lipoprotein flocculant (polyethylene glycol, sodium dextran sulfate, polyacrylic acid resin, Food thickening stabilizers), salting out such as ammonium sulfate precipitation, filtration such as ultrafiltration, degreasing method using ethanol and supercritical carbon dioxide extraction in combination.
本発明で用いられる卵黄抗体は、目的の抗原に対する結合能を有していれば特に限定されず、完全な状態の抗体以外に、抗体の分解物であるF(ab′)2、Fab′、Fab等であってもよい。これらは単独で用いられてもよく、2種以上が併用されてもよい。また、複数種類の抗原に対する抗体を併用してもよい。 The egg yolk antibody used in the present invention is not particularly limited as long as it has the ability to bind to the target antigen. In addition to the intact antibody, F (ab ′) 2 , Fab ′, It may be Fab or the like. These may be used independently and 2 or more types may be used together. Moreover, you may use together the antibody with respect to multiple types of antigen.
本発明に係る高保存性抗体溶液における卵黄抗体の濃度は、卵黄抗体として凍結乾燥品を用いた場合、1μg/mL〜20mg/mLであることが好ましく、より好ましくは8μg/mL〜10mg/mLである。1μg/mL未満であると、充分な量の卵黄抗体をマスク等へ吹き付けることが難しく、20mg/mLを超えると、卵黄抗体の凝集等が起こることがある。 The concentration of the yolk antibody in the highly conserved antibody solution according to the present invention is preferably 1 μg / mL to 20 mg / mL, more preferably 8 μg / mL to 10 mg / mL when a freeze-dried product is used as the yolk antibody. It is. When it is less than 1 μg / mL, it is difficult to spray a sufficient amount of egg yolk antibody onto a mask or the like, and when it exceeds 20 mg / mL, aggregation of egg yolk antibody may occur.
本発明で用いられる水としては特に限定されず、水道水であってもよいが、脱イオン水や超純水等が好適に用いられる。 It does not specifically limit as water used by this invention, Although tap water may be sufficient, deionized water, ultrapure water, etc. are used suitably.
本発明に係る高保存性抗体溶液は、1〜25質量%のエタノールを含有している。エタノール濃度が1質量%未満であると、充分な保存性を得るためには精度の高い滅菌処理が必要となり、エタノール濃度が25質量%を超えると、保存中に抗体が変性し活性が低下してしまう。当該エタノール濃度の、好ましい下限は5質量%であり、より好ましい下限は10質量%である。また、好ましい上限は20質量%であり、より好ましい上限は15質量%である。 The highly conserved antibody solution according to the present invention contains 1 to 25% by mass of ethanol. If the ethanol concentration is less than 1% by mass, high-precision sterilization is necessary to obtain sufficient storage stability. If the ethanol concentration exceeds 25% by mass, the antibody is denatured during storage and the activity decreases. End up. A preferable lower limit of the ethanol concentration is 5% by mass, and a more preferable lower limit is 10% by mass. Moreover, a preferable upper limit is 20 mass% and a more preferable upper limit is 15 mass%.
本発明に係る高保存性抗体溶液は、必要に応じて香料や緩衝剤等を含有してもよい。前記香料としては、例えば、メントール、D−リモネン、デシルアルデヒド、メントン、プレゴン、オイゲノール、シンナムアルデヒド、ベンズアルデヒド、ペパーミント油、レモン油、オレンジ油等が挙げられる。前記緩衝剤としては一般的にタンパク質に用いられるものであれば特に限定されず、例えば、リン酸緩衝液、酢酸緩衝液、ホウ酸緩衝液、グリシン緩衝液、トリス緩衝液、グッドの緩衝液等の緩衝液を調製するためのものが挙げられる。 The highly conserved antibody solution according to the present invention may contain a fragrance, a buffering agent or the like as necessary. Examples of the fragrances include menthol, D-limonene, decylaldehyde, menthone, pulegone, eugenol, cinnamaldehyde, benzaldehyde, peppermint oil, lemon oil, orange oil and the like. The buffer is not particularly limited as long as it is generally used for proteins. For example, phosphate buffer, acetate buffer, borate buffer, glycine buffer, Tris buffer, Good's buffer, etc. For preparing a buffer solution of
本発明に係る高保存性抗体溶液のpHとしては特に限定されないが、中性付近(例えば、pH6〜8)であればよい。 Although it does not specifically limit as pH of the highly-storable antibody solution based on this invention, What is necessary is just near neutrality (for example, pH 6-8).
本発明に係る高保存性抗体溶液には、滅菌処理を施すことが必要である。当該滅菌処理としては抗体活性を低下させない方法であれば特に限定されないが、フィルター滅菌が好適に用いられる。フィルター滅菌を用いれば、粗精製品である卵黄抗体を用いた場合、滅菌とともに卵黄抗体の精製を行うことも可能となる。 The highly conserved antibody solution according to the present invention needs to be sterilized. The sterilization treatment is not particularly limited as long as it does not reduce antibody activity, but filter sterilization is preferably used. If filter sterilization is used, when an egg yolk antibody, which is a crude product, is used, it becomes possible to purify the egg yolk antibody together with sterilization.
前記フィルター滅菌に用いるフィルターとしては、孔径が0.50μm以下のものが好ましく、より好ましくは孔径が0.25μm以下のものである。孔径が0.50〜0.25μmであると、一部の細菌は通過可能であるが、本発明に係る高保存性抗体溶液はエタノールを含有しているので、腐敗は起こらない。フィルターの孔径が0.25μm以下であれば、略完全に細菌を除去することができる。 The filter used for filter sterilization preferably has a pore size of 0.50 μm or less, and more preferably has a pore size of 0.25 μm or less. When the pore size is 0.50 to 0.25 μm, some bacteria can pass through, but since the highly conserved antibody solution according to the present invention contains ethanol, no spoilage occurs. If the pore size of the filter is 0.25 μm or less, bacteria can be removed almost completely.
本発明に係る高保存性抗体溶液を製造するには、まず、卵黄抗体を水(脱イオン水、超純水等)や緩衝液等の水性溶媒に溶解して抗体溶液を調製し、次いで、抗体溶液をフィルター滅菌する。抗体溶液へのエタノールの添加はフィルター滅菌が施される前であってもよく、後であってもよい。 To produce a highly conserved antibody solution according to the present invention, first, an antibody solution is prepared by dissolving an egg yolk antibody in an aqueous solvent such as water (deionized water, ultrapure water, etc.) or a buffer solution, Filter sterilize the antibody solution. The ethanol may be added to the antibody solution before or after filter sterilization.
得られた高保存性抗体溶液を滅菌済みの密閉容器内に収容すれば、長期間安定して保存することができる。また、前記密閉容器としてスプレー容器を用いれば、マスク等に抗体溶液を吹き付けて抗菌性や抗ウイルス性等を付与するためのスプレーとして用いることができる。 If the obtained highly-storable antibody solution is accommodated in a sterilized sealed container, it can be stably stored for a long period of time. In addition, if a spray container is used as the closed container, it can be used as a spray for imparting antibacterial and antiviral properties by spraying an antibody solution onto a mask or the like.
また、得られた高保存性抗体溶液を用いてエアゾール製品を構成してもよい。この場合、滅菌済みの密閉容器内に高保存性抗体溶液とともに充填する噴射剤としては、液体中の抗体活性を低下させないために、窒素ガスを用いることが望ましい。また、前記密閉容器内にメチルパラベン等の防腐剤を入れても良い。防腐剤としてメチルパラベンを用いることで、エアゾール化に伴う爆発の心配がない。 Moreover, you may comprise an aerosol product using the obtained highly conserved antibody solution. In this case, it is desirable to use nitrogen gas as a propellant filled together with a highly-storable antibody solution in a sterilized sealed container so as not to reduce antibody activity in the liquid. Moreover, you may put antiseptic | preservatives, such as methyl paraben, in the said airtight container. By using methylparaben as a preservative, there is no worry of explosion associated with aerosolization.
以下に実施例を掲げて本発明を更に詳細に説明するが、本発明はこれら実施例のみに限定されるものではない。 The present invention will be described in more detail with reference to the following examples. However, the present invention is not limited to these examples.
以下のようにして調製した抗体溶液を用いて、その抗体価の経時変化を観察した。 Using an antibody solution prepared as follows, the antibody titer was observed over time.
<被試験抗体>
被試験抗体として、コナヒョウヒダニ虫体由来粗精製アレルゲン又はヤケヒョウヒダニ虫体由来粗精製アレルゲンにより免疫したニワトリに産生させたIgYを、硫安沈澱により粗精製し、これを凍結乾燥してなる粉末状の抗体を用いた。
<Test antibody>
As an antibody to be tested, a powdered antibody obtained by roughly purifying IgY produced in a chicken immunized with a crudely purified allergen derived from an Aedes acarina mite or a crudely purified allergen derived from an Aedes albopictus by ammonium sulfate precipitation and freeze-dried. Using.
<抗体溶液の調製>
PBS(−)に上記の各IgY粉末を10mg/mL濃度になるよう溶解して、完全に溶解させた後、孔径0.45μmのフィルターを用いて滅菌を行った。並行して、脱イオン水に95%エタノールを10、20、40、60、80質量%の濃度になるように加えて、濃度の異なるエタノール水溶液を調製した。各濃度のエタノール水溶液と滅菌済みIgY水溶液とを1:1で混合した後、得られた抗体溶液を1.0mLずつスクリューキャップチューブに分注し、37℃で遮光して静置保存した。
<Preparation of antibody solution>
The above IgY powders were dissolved in PBS (−) to a concentration of 10 mg / mL and completely dissolved, and then sterilized using a filter having a pore diameter of 0.45 μm. In parallel, 95% ethanol was added to deionized water to a concentration of 10, 20, 40, 60, and 80 mass% to prepare ethanol aqueous solutions having different concentrations. After mixing ethanol aqueous solution of each concentration and sterilized IgY aqueous solution 1: 1, the obtained antibody solution was dispensed into a screw cap tube in an amount of 1.0 mL, and stored at 37 ° C. with light shielding.
<抗体価(力価)の測定>
各抗体溶液を1週間保存後及び34週間保存後(加速試験)にサンプリングして、各抗体溶液中のIgYの抗体価の維持率を、各アレルゲン固相化プレートを用いてELISAにより測定した。なお、0週目(試験開始時)及び1週間保存後の各抗体溶液は、サンプリング後−30℃で凍結保存し、34週間保存後の各抗体溶液とともに抗体価の測定に供した。
<Measurement of antibody titer (titer)>
Each antibody solution was sampled after storage for 1 week and 34 weeks (acceleration test), and the maintenance rate of the antibody titer of IgY in each antibody solution was measured by ELISA using each allergen-immobilized plate. Each antibody solution stored at 0 week (at the start of the test) and after 1 week was stored frozen at −30 ° C. after sampling, and subjected to antibody titer measurement together with each antibody solution stored for 34 weeks.
得られた結果は、抗コナヒョウヒダニ虫体由来粗精製アレルゲンIgYの抗体価を下記表1及び図1のグラフに示し、抗ヤケヒョウヒダニ虫体由来粗精製アレルゲンIgYの抗体価を下記表2及び図2のグラフに示す。また、各エタノール濃度の抗コナヒョウヒダニ虫体由来粗精製アレルゲンIgYの抗体溶液を1週間保存した後の様子を図3の写真に示す。 The obtained results show the antibody titers of the crude purified allergen IgY derived from the anti-carp leopard mite body in the following Table 1 and the graph of FIG. Shown in the graph. Moreover, the mode after preserve | saving the antibody solution of the crude purified allergen IgY derived from the anti-carp leopard mite parasite of each ethanol concentration for one week is shown in the photograph of FIG.
なお、表1及び表2中、「−」と記載されている箇所は、測定不能であったことを示す。 In Tables 1 and 2, “-” indicates that measurement was impossible.
<結果>
抗コナヒョウヒダニ虫体由来粗精製アレルゲンIgYの抗体溶液では、表1及び図1に示すように、エタノール濃度が5質量%、10質量%、20質量%及び25質量%である場合は、1週間保存後でも抗体価が90%前後維持されており、34週間保存後でも抗体価が40%前後も維持されていた。一方、エタノール濃度が30質量%の抗体溶液の抗体価維持率は1週間保存後には約50%にまで低下し、34週間保存後には約20%にまで低下した。更に、エタノール濃度が40質量%の抗体溶液の抗体価維持率は1週間保存後で約20%にまで低下した。また、図3に示すように、1週間保存後において、エタノール濃度が30質量%及び40質量%の抗体溶液は白濁しているのに対して、エタノール濃度が5質量%、10質量%及び20質量%の抗体溶液では白濁は認められなかった。なお、エタノール濃度が40質量%の抗体溶液は、エタノール水溶液の混合直後から白濁した。
<Result>
As shown in Table 1 and FIG. 1, the antibody solution of the anti-Pleurotus mite parasite-derived crude purified allergen IgY is stored for 1 week when the ethanol concentration is 5% by mass, 10% by mass, 20% by mass, and 25% by mass. Later, the antibody titer was maintained at around 90%, and the antibody titer was maintained at around 40% even after storage for 34 weeks. On the other hand, the antibody titer maintenance rate of the antibody solution having an ethanol concentration of 30% by mass decreased to about 50% after storage for 1 week and decreased to about 20% after storage for 34 weeks. Furthermore, the antibody titer maintenance rate of the antibody solution having an ethanol concentration of 40% by mass decreased to about 20% after storage for 1 week. In addition, as shown in FIG. 3, after storage for 1 week, antibody solutions with ethanol concentrations of 30% by mass and 40% by mass are cloudy, whereas ethanol concentrations are 5% by mass, 10% by mass, and 20%. White turbidity was not observed in the mass% antibody solution. The antibody solution having an ethanol concentration of 40% by mass became cloudy immediately after mixing the ethanol aqueous solution.
また、抗ヤケヒョウヒダニ虫体由来粗精製アレルゲンIgYの抗体溶液では、表2及び図2に示すように、エタノール濃度が5質量%、10質量%、20質量%及び25質量%である場合は、1週間保存後では抗体価はほとんど低下しておらず、34週間保存後でも抗体価は約40%以上も維持されていた。一方、エタノール濃度が30質量%の抗体溶液の抗体価維持率は1週間保存後には約50%にまで低下し、34週間保存後には約20%にまで低下した。更に、エタノール濃度が40質量%の抗体溶液の抗体価維持率は1週間保存後には約25%にまで低下した。 In addition, in the antibody solution of the anti-Dark leopard mite parasite-derived crude purified allergen IgY, as shown in Table 2 and FIG. 2, when the ethanol concentration is 5% by mass, 10% by mass, 20% by mass, and 25% by mass, 1 The antibody titer hardly decreased after weekly storage, and the antibody titer was maintained at about 40% or more after 34 weeks of storage. On the other hand, the antibody titer maintenance rate of the antibody solution having an ethanol concentration of 30% by mass decreased to about 50% after storage for 1 week and decreased to about 20% after storage for 34 weeks. Furthermore, the antibody titer maintenance rate of the antibody solution having an ethanol concentration of 40% by mass decreased to about 25% after storage for 1 week.
Claims (7)
前記抗体溶液をフィルター滅菌する工程と、
フィルター滅菌が施される前又は後の抗体溶液に、1〜25質量%の濃度となるようにエタノールを加える工程と、を有することを特徴とする高保存性抗体溶液の製造方法。 Dissolving an egg yolk antibody in an aqueous solvent to prepare an antibody solution;
Filter sterilizing the antibody solution;
And a step of adding ethanol to the antibody solution before or after filter sterilization so as to obtain a concentration of 1 to 25% by mass.
前記抗体溶液をフィルター滅菌する工程と、
フィルター滅菌が施される前又は後の抗体溶液に、1〜25質量%の濃度となるようにエタノールを加える工程と、
前記抗体溶液を滅菌済みの密閉容器内に収容する工程と、を有することを特徴とする抗体の保存方法。 Dissolving an egg yolk antibody in an aqueous solvent to prepare an antibody solution;
Filter sterilizing the antibody solution;
Adding ethanol to the antibody solution before or after filter sterilization to a concentration of 1 to 25% by mass;
And storing the antibody solution in a sterilized sealed container.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014079671A JP2014218496A (en) | 2013-04-08 | 2014-04-08 | Highly-preservable antibody solution |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013080257 | 2013-04-08 | ||
JP2013080257 | 2013-04-08 | ||
JP2014079671A JP2014218496A (en) | 2013-04-08 | 2014-04-08 | Highly-preservable antibody solution |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2014218496A true JP2014218496A (en) | 2014-11-20 |
Family
ID=51937305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014079671A Pending JP2014218496A (en) | 2013-04-08 | 2014-04-08 | Highly-preservable antibody solution |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2014218496A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019024311A1 (en) * | 2017-08-02 | 2019-02-07 | Wwhs Biotech, Inc | Solution and method for preserving fluorescent antibody |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0253716A (en) * | 1988-08-18 | 1990-02-22 | Lion Corp | Composition for oral cavity application |
JP2002510601A (en) * | 1998-04-06 | 2002-04-09 | イノセント リミテッド | Oral antimicrobial and deodorant composition |
JP2003159094A (en) * | 2001-11-26 | 2003-06-03 | Japan Science & Technology Corp | Method for aseptically producing yolk antibody |
JP2003212898A (en) * | 2002-01-22 | 2003-07-30 | Pharmafoods Kenkyusho:Kk | Method for producing yolk antibody |
JP2005169105A (en) * | 2003-03-28 | 2005-06-30 | Daikin Ind Ltd | Mask equipped with noxious substance eliminating material for mask, and storage method for noxious substance eliminating material for mask |
JP2009528352A (en) * | 2006-03-01 | 2009-08-06 | デンテック インコーポレイテッド | Oral hygiene products and their use |
JP2010516688A (en) * | 2007-01-16 | 2010-05-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Antibacterial peptide |
-
2014
- 2014-04-08 JP JP2014079671A patent/JP2014218496A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0253716A (en) * | 1988-08-18 | 1990-02-22 | Lion Corp | Composition for oral cavity application |
JP2002510601A (en) * | 1998-04-06 | 2002-04-09 | イノセント リミテッド | Oral antimicrobial and deodorant composition |
JP2003159094A (en) * | 2001-11-26 | 2003-06-03 | Japan Science & Technology Corp | Method for aseptically producing yolk antibody |
JP2003212898A (en) * | 2002-01-22 | 2003-07-30 | Pharmafoods Kenkyusho:Kk | Method for producing yolk antibody |
JP2005169105A (en) * | 2003-03-28 | 2005-06-30 | Daikin Ind Ltd | Mask equipped with noxious substance eliminating material for mask, and storage method for noxious substance eliminating material for mask |
JP2009528352A (en) * | 2006-03-01 | 2009-08-06 | デンテック インコーポレイテッド | Oral hygiene products and their use |
JP2010516688A (en) * | 2007-01-16 | 2010-05-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Antibacterial peptide |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019024311A1 (en) * | 2017-08-02 | 2019-02-07 | Wwhs Biotech, Inc | Solution and method for preserving fluorescent antibody |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2728575C1 (en) | Stabilized preparations containing antibodies against ngf | |
TWI445714B (en) | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use | |
JP2018203784A (en) | Stabilization of immunoglobulin through aqueous formulation with histidine at weak acidic to neutral ph | |
ES2584190T3 (en) | Procedure for the manufacture of a pharmaceutical preparation containing glatiramer acetate | |
EP1958626B1 (en) | Method for inactivating viruses by addition of slightly acidic arginine | |
EA028227B1 (en) | Stabilized formulations containing antibodies to human proprotein convertase subtilisin/kexin type 9 (pcsk9) | |
JP2017222654A5 (en) | ||
MX2010011117A (en) | Aqueous pharmaceutical formulation. | |
AR082257A1 (en) | COMPOSITION OF CONCENTRATED HUMAN IMMUNOGLOBULINS, PROCEDURE | |
US20160251261A1 (en) | Method of Handling a Liquid Drug Formation | |
ZA202102986B (en) | Protein solution formulation containing high concentration of an anti-vegf antibody | |
JP2014218496A (en) | Highly-preservable antibody solution | |
JP2022546275A (en) | Stable medicinal products containing diluted povidone-iodine preparations | |
US8501220B2 (en) | Stabilized liquid egg material for extended shelf life | |
RU2019111152A (en) | NEW METHOD FOR STABILIZING BIOPHARMACEUTICAL MEDICINAL PRODUCT IN PRODUCTION | |
WO2018102145A1 (en) | Levothyroxine liquid formulations | |
PT92163B (en) | METHOD FOR PREPARING A LIOFILIZED MDM COMPOSITION | |
CA2390897A1 (en) | Method of improving hatchability of eggs | |
CN104412970B (en) | Natural latex vessel disinfectant and using method thereof | |
US9408804B2 (en) | Method for keeping an immunogenic composition available for administration to an animal | |
RU2561596C2 (en) | Method for producing virus-inactivated immunoglobulin solutions low in residual caprylic acid | |
RU2521513C1 (en) | Application of aethonium as adjuvant for production of sorbed foot-mouth disease vaccine | |
WO2019226058A1 (en) | Medicinal product containing improved stability water solution of methisoprinol | |
US20160144033A1 (en) | Concentrated acetaminophen solution | |
US20240209066A1 (en) | 2019 novel coronavirus antibody-containing pharmaceutical formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170307 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180131 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180621 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181101 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190423 |